Meds, Mind, Body & Benefits > Research News & Studies

Another Therapeutic HIV Vaccine in Support of the "Cure Agenda". PHASE I



An NIAID-conducted Phase 1 Study Will Assess the Safety and Immunogenicity of the Profectus Multi-Antigen HIV DNA Vaccine in Formulation with Profectus' GENEVAX(TM) IL-12 Adjuvant when Delivered by Electroporation to prime the immune response followed by booster immunization with the Profectus recombinant Vesicular Stomatitis Virus (rVSV)-Vectored HIV Vaccine in HIV-infected Adults on Antiretroviral Therapy. In addition, the ability of the "prime boost" vaccination regimen to address the goals of the HIV cure agenda by targeting the latent reservoir and eradicating HIV will be evaluated.


[0] Message Index

Go to full version